Lung Cancer
Conditions
Keywords
Bronchoscopy, Ablation, Microwave, Lung cancer
Brief summary
The overall purpose of this study is to characterise the clinical safety and performance of the Creo Medical MicroBlate™ Flex AB1 instrument in patients with pathologically confirmed malignancy eligible for surgical resection of their nodule, receiving bronchoscopic ablation prior to surgery.
Detailed description
This is a post-market, prospective, single-arm, multicentre, open-label, non-randomised study which will enrol up to 30 subjects in total (plus replacements if required due to drop out). Prospective patients must have a histopathological-confirmed malignant lung lesion and be candidates for surgical resection. After being informed about the study and potential risks, all patients giving their written informed consent will undergo a screening visit to determine eligibility for study entry. The study consists of two (2) stages (Stage A and Stage B). Stage A consists of the ablation and surgical resection being performed concurrently on Day 0 within a single procedure. Stage B consists of the ablation and the surgical resection being performed in separate procedures. The surgical resection will occur between Day 7 and Day 21, post-ablation, inclusive of those days. The aim is to follow local guidelines for treatment of lung cancer. Patients undergoing Stage A will be released from the study at point of standard of care discharge from hospital post-surgery and will not be followed as part of the study (patients will receive SoC follow-up and care post release from study). Patients undergoing Stage B will have evaluations at follow-up visits conducted at 7 (+/-3) days (via phone call) post ablation and prior to the surgical resection procedure. Stage B patients will be released from the study at point of standard of care discharge from hospital post-surgery and will not be followed as part of the study (patients will receive SoC follow-up and care post release from study).
Interventions
DEVICEAblation
Bronchoscopy and microwave ablation prior to surgical resection.
Sponsors
Creo Medical Limited
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients who: 1. Have signed informed consent. 2. Subject is willing and able to comply with all aspects of the treatment and evaluation schedule. 3. Are ≥ 18 years old. 4. Have lung lesion(s)/nodule(s) which are histopathological-confirmed as cancer. 5. Have soft tissue lung lesion(s): * ≤ 30 mm in the largest dimension of the pulmonary window for Stage A. * ≤ 20 mm in the largest dimension of the pulmonary window for Stage B. 6. Are candidates for surgical resection as determined by a multi-disciplinary team (MDT) or tumour board. 7. Greater than 10 mm of tumour-free lung parenchyma between target tumour and pleura or fissure. 8. Subject is willing and able to comply with the study protocol requirements. 9. Are assigned an ASA (American Society of Anaesthesiologists) score of ≤ 3 or the patient is deemed fit for general anaesthesia.
Exclusion criteria
Patients who: 1. Have target nodule(s) within the International Association for the Study of Lung Cancer (IASLC) "Central Zone" (including bronchial tree, major vessels, heart, oesophagus, spinal cord, and phrenic \& laryngeal nerves). 2. Are pregnant or breast feeding, as determined by standard site practices. 3. Have participated in an investigational drug or device research study within 30 days of enrolment that would interfere with this study. 4. Have a physical or psychological condition that would impair study participation or jeopardise the safety or welfare of the subject. 5. Have an expected survival less than 12 months. 6. Have bleeding diathesis, uncorrectable coagulopathy, or platelet count ≤ 100 x 10\^9/L. 7. Have an implantable device, including pacemakers or other electronic implants. 8. Have known pulmonary hypertension (PASP \[pulmonary artery systolic pressure\] \>50mmHg). 9. Who are currently prescribed anticoagulants, clopidogrel or other platelet aggregation inhibitors which can´t be stopped or temporarily withheld. 10. Subject had a prior pneumonectomy. 11. Diagnosis of Small Cell Lung Cancer. 12. Any patient with clinically significant interstitial lung disease in the zone of planned ablation. 13. Subject had a therapeutic intervention (e.g., SBRT) within same lobe as the target lesion. 14. Subjects currently undergoing or underwent chemotherapy, systemic immunosuppressive treatment, or radiotherapy within 3 months of planned Study procedure.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary Safety Endpoint | Day 0, day of ablation procedure up to initiation of surgical resection procedure. | Stage A - Ablate (Day 0) \& Resect (Day 0) Identification of serious device-related intra-procedural adverse events related to the use of the AB1 system on Day 0 prior to surgical resection defined by the initial skin incision (number and nature of serious adverse events, both device and procedure related, will be identified). |
| Primary Performance (Efficacy) Endpoint | Up to 1 week post ablation procedure. | Initial technical success, defined as successful bronchoscopic access by the AB1 instrument of the target tissue, delivery of scheduled microwave energy to the target tissue (per pre-specified target) and confirmed ablation as evidenced by macroscopic assessment post-surgical resection of the ablated lesion. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Secondary Performance (Efficacy) Endpoints - Assessment/visualization/quantification of the dimensions of the ablated tissue including assessment of margin relative to lesion | Up to 1 week post ablation procedure. | Dimensions of the ablated tissue to confirm, correct or add to the IFU-reported relationship between AB1 ablation time and dimensions and volume of the ablated tissue, per pre-specified target. |
| Secondary Performance (Efficacy) Endpoints - Assessment/visualization/quantification of the dimensions of the ablation observed within the post-ablation CT | Up to 1 week post ablation procedure. | Dimensions of the ablated tissue as evidenced on the post ablation CT. |
| Secondary Performance (Efficacy) Endpoints - Procedural Time | Up to 1 week post ablation procedure. | Procedural time to be captured in the electronic case report form (eCRF). |
| Secondary Performance (Efficacy) Endpoints - Assessment of ease of system use (clinician questionnaires) | Up to 1 week post ablation procedure. | Questionnaires to be completed by clinicians, rating their responses on a Likert scale of 1 to 7, with 1 being "extremely clear/easy" and 7 being "extremely difficult". |
Countries
Netherlands
Contacts
CONTACTCharlie Campion
CONTACTAnnie Goulding
PRINCIPAL_INVESTIGATORJouke T Annema, MD
Amsterdam University Medical Centres
Outcome results
None listed